802 related articles for article (PubMed ID: 28094038)
1. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
2. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
3. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.
Luttmer R; Dijkstra MG; Snijders PJ; Berkhof J; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; van Baal WM; Graziosi PG; Quint WG; Spruijt JW; van Dijken DK; Heideman DA; Meijer CJ
Mod Pathol; 2016 Aug; 29(8):870-8. PubMed ID: 27150161
[TBL] [Abstract][Full Text] [Related]
4. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
5. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
Stoler MH; Baker E; Boyle S; Aslam S; Ridder R; Huh WK; Wright TC
Int J Cancer; 2020 May; 146(9):2599-2607. PubMed ID: 31490545
[TBL] [Abstract][Full Text] [Related]
6. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
7. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
[TBL] [Abstract][Full Text] [Related]
8. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
9. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
[TBL] [Abstract][Full Text] [Related]
10. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M
Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
12. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
13. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
Petry KU; Schmidt D; Scherbring S; Luyten A; Reinecke-Lüthge A; Bergeron C; Kommoss F; Löning T; Ordi J; Regauer S; Ridder R
Gynecol Oncol; 2011 Jun; 121(3):505-9. PubMed ID: 21420158
[TBL] [Abstract][Full Text] [Related]
14. p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old.
Pirtea L; Secosan C; Margan M; Moleriu L; Balint O; Grigoras D; Sas I; Horhat F; Jianu A; Ilina R
Bosn J Basic Med Sci; 2019 Nov; 19(4):336-341. PubMed ID: 29924960
[TBL] [Abstract][Full Text] [Related]
15. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.
Ebisch RM; van der Horst J; Hermsen M; Rijstenberg LL; Vedder JE; Bulten J; Bosgraaf RP; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Massuger LF; Melchers WJ; Bekkers RL; Siebers AG
Mod Pathol; 2017 Jul; 30(7):1021-1031. PubMed ID: 28304400
[TBL] [Abstract][Full Text] [Related]
17. Clinical validation of p16/Ki-67 dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial.
Wright TC; Stoler MH; Ranger-Moore J; Fang Q; Volkir P; Safaeian M; Ridder R
Int J Cancer; 2022 Feb; 150(3):461-471. PubMed ID: 34536311
[TBL] [Abstract][Full Text] [Related]
18. Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.
Wentzensen N; Clarke MA; Bremer R; Poitras N; Tokugawa D; Goldhoff PE; Castle PE; Schiffman M; Kingery JD; Grewal KK; Locke A; Kinney W; Lorey TS
JAMA Intern Med; 2019 Jul; 179(7):881-888. PubMed ID: 31081870
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
[TBL] [Abstract][Full Text] [Related]
20. Dual p16 and Ki-67 Expression in Liquid-Based Cervical Cytological Samples Compared to Pap Cytology Findings, Biopsies, and HPV Testing in Cervical Cancer Screening: A Diagnostic Accuracy Study.
Prigenzi KCK; Heinke T; Salim RC; Focchi GRA
Acta Cytol; 2018; 62(2):104-114. PubMed ID: 29566392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
